Tanvex BioPharma, Inc. (TWSE: 6541) is a biopharmaceutical company focused on the biopharmaceutical market, especially biosimilar and CDMO. The
company has successfully brought its first product (NYPOZI™, filgrastim biosimilar) to approval in Canada, and additional BLAs are pending approval by the FDA. The company is vertically integrated with end-to-end in-house development, manufacturing and commercialization capabilities. Tanvex BioPharma, Inc. is registered in Cayman Islands and has operations and facilities in Irvine, CA, SanDiego, CA, and Taipei, Taiwan. Tanvex is publicly traded on the Taiwan Stock Exchange.